Immunoglobulin E vaccine - Pfizer

Drug Profile

Immunoglobulin E vaccine - Pfizer

Alternative Names: Anti-IgE vaccine - Pfizer; Anti-immunoglobulin-E vaccine - Pfizer; IGE-1; IGE-2; PF-06444752; PF-06444753; PF-6444752; PF-6444753

Latest Information Update: 22 Mar 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Allergy immunotherapies; Vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Asthma; Perennial allergic rhinitis

Most Recent Events

  • 22 Mar 2016 Safety and immunogenicity data from a phase I trial in Asthma was presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2016)
  • 28 Oct 2015 Discontinued - Phase-I for Asthma (IM)
  • 28 Oct 2015 Discontinued - Phase-I for Perennial allergic rhinitis in Canada (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top